INDEX TO AUTHORS

A

ABELSON, L. See MANN, ABELSON, HARRIS, and AMOS 84
ABRAMSKY, ODED. See TARRAB-HAZDI, AHARONOV, ABRAMSKY, YAAR, and FUCHS 785
ACS, GEORGE. See CHRISTMAN, SILVERSTEIN, and ACS 419
ACTON, RONALD T. See ZWERNER and ACTON 378
ADLER, FRANK L. See ADLER and ADLER 332
ADLER, LOUISE T., and ADLER, FRANK L. In vitro studies on allotype suppression. III. Components of antiallotype serum active in release from allotype suppression 332
AHARONOV, AHARON. See TARRAB-HAZDI, AHARONOV, ABRAMSKY, YAAR, and FUCHS 785
ALBRECHT, PAUL. See SULLIVAN, BARRY, LUCAS, and ALBRECHT 773
ALDO-BENSON, MARLENE A. See BENSON, ALDO-BENSON, SHIRAHAMA, BOREL, and COHEN 236
ALTMAN, AMNON, and COHEN, IRUN R. Heterogeneity in the development of cytotoxic T lymphocytes in vitro revealed by sensitivity to hydrocortisone 790
AMOS, D. B. See MANN, ABELSON, HARRIS, and AMOS 84
ANDERSSON, LEIF C. See KONTIAINEN and ANDERSSON 1035
ANDRÉ, CLAUDE, HEREMANS, JOSEPH F., VAERMAN, JEAN PIERRE, and CAMBIASO, CESAR L. A mechanism for the induction of immunological tolerance by antigen feeding: antigen-antibody complexes 1509
ARBEIT, ROBERT D. See RYAN, ARBEIT, DICKLER, and HENKART 814
ARMSTRONG, J. A., and HART, P. D'ARCY. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival 1
ARNON, RUTH. See TEITELBAUM, WEBB, RAUCH, KARNIELY, ARNON, and SELA 701
ASKENASE, PHILIP W. See GERSHON, ASKENASE, and GERSHON 732
AUERBACH, ROBERT. See WU, BACH, and AUERBACH 1301
AUSTEN, K. FRANK. See FEARON and AUSTEN 856
AXLINE, STANTON G. See PESANTI and AXLINE 903
AYVAZIAN, J. H. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120

B

BACH, FRITZ H. See SONDEL and BACH 1339
—. See SONDEL, JACOBSON, and BACH 1606
—. See WU, BACH, and AUERBACH 1301
BACHVAROFF, R. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120
BALNER, HANS. See DORF, BALNER, and BENACERRAF 673
BARRY, DAVID W. See SULLIVAN, BARRY, LUCAS, and ALBRECHT 773
BASH, JERRY A., DURKIN, HELEN G., and WAKSMAN, BYRON H. Kinetic study of T lymphocytes after sensitization against soluble antigen. III. Potentiation and suppression of the PHA response by antigen-activated lymphocytes of low density 1017
BASHAM, CONNIE. See CURRIE and BASHAM 1600
BEER, ALAN E., SCOTT, JAMES R., and BILLINGHAM, R. E. Histoincompatibility and maternal immunological status as determinants of fetoplacental weight and litter size in rodents 180
BENACERRAF, BARUJ. See BULLOCK, KATZ, and BENACERRAF 261, 275
—. See DEBRÉ, KAPP, and BENACERRAF 1436
—. See DEBRÉ, KAPP, DORF, and BENACERRAF 1447
—. See DORF, BALNER, and BENACERRAF 673
—. See GERMAIN, DORF, and BENACERRAF 1023
—. See KAPP, PIERCE, and BENACERRAF 50
BENNETT, J. CLAUDE. See HURST, VOLANAKIS, STROUD, and BENNETT 1322
BEN-SASSON, S. Z., PAUL, WILLIAM E., SHEVACH, ETHAN M., and GREEN, IRA. In vitro selection and extended culture of antigen-specific T lymphocytes. I. Description of selection culture procedure and initial characterization of selected cells 90
BENSON, MERRILL D., ALDO-BENSON, MARLENE A., SHIRAHAMA, TSURANOBU, BOREL, YVES, and COHEN, ALAN S. Suppression of in vitro antibody response by a serum factor (SAA) in experimentally induced amyloidosis 236
BERKE, GIDEON, and FISHELSON, ZVI. Localization of aggregated cell surface antigens of target cells bound to cytotoxic T lymphocytes 1011
BERNING, ALICE K. See SCHER, STEINBERG, BERNING, and PAUL 637
BEVAN, MICHAEL JOHN. The major histocompatibility complex determines susceptibility to

cytotoxic T cells directed against minor histocompatibility antigens 1349
BHATNAGAR, RAJESH M., ZABRISKIE, JOHN B., and RAUSEN, AARON R. Cellular immune responses to methylcholanthrene-induced fibrosarcoma in BALB/c mice 839
BIANCO, CELSO. See NOGUEIRA, BIANCO, and COHN 224
BILLINGHAM, R. E. See BEER, SCOTT, and BILLINGHAM 180
BINZ, HANS, and WIGZELL, HANS. Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. I. Demonstration of similar or identical idiotypes on IgG molecules and T-cell receptors with specificity for the same alloantigens 197
— and —. II. Determination of frequency and characteristics of idiotypic T and B lymphocytes in normal rats using direct visualization 1218
— and —. III. Physical fractionation of specific immunocompetent T lymphocytes by affinity chromatography using anti-idiotypic antibodies 1231
BLOOM, BARRY R., and SHEVACH, ETHAN. Requirement for T cells in the production of migration inhibitory factor 1306
BLUMENSTOCK, D. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120
BOKISCH, V. A. See HARTMANN and BOKISCH 600
—. See SOBEL, BOKISCH, and MÜLLER-EBERHARD 139
BOREL, YVES, REINISCH, CAROL L., and SCHLOSSMAN, STUART F. T and B cell in hapten-specific carrier-determined tolerance 1154
—. See BENSON, ALDO-BENSON, SHIRAHAMA, BOREL, and COHEN 236
BOSMA, M. J. See HAUSMAN and BOSMA 998
BOYSE, EDWARD A. See STOCKERT, BOYSE, OBATA, IKEDA, SARKAR, and HOFFMAN 512
—. See TUNG, FLEISSNER, VITETTA, and BOYSE 518
BRAUN, VOLKMAR. See MELCHERS, BRAUN, and GALANOS 473
BRITTON, SVEN. Experimental amyloidosis: the inducer is a polyclonal B-cell activator to which susceptibility is under genetic control 1564
BRODY, JACOB. See VIOLA, FRAZIER, WHITE, BRODY, and SPIEGELMAN 483
BRUNNER, K. THEODOR. See MACDONALD, SORDAT, CEROTTINI, and BRUNNER 622
BULLOCK, WESLEY W., KATZ, DAVID H., and BENACERRAF, BARUJ. Induction of T-lymphocyte responses to a small molecular weight antigen. II. Specific tolerance induced in azobenzenearsonate (ABA)-specific T cells in guinea pigs by administration of low doses of an ABA conjugate of chloroacetyl tyrosine in incomplete Freund's adjuvant 261
—, —, and —. III. T-T cell interactions to determinants linked together: suppression vs. enhancement 275

C

CALDERON, JESUS, KIELY, JEANNE-MARIE, LEFKO, JANET L., and UNANUE, EMIL R. The modulation of lymphocyte functions by molecules secreted by macrophages. I. Description and partial biochemical analysis 151
CAMBIASO, CESAR L. See ANDRÉ, HEREMANS, VAERMAN, and CAMBIASO 1509
CAMPBELL, ROSALIE. See TAUSSIG, MUNRO, CAMPBELL, DAVID, and STAINES 694
CANNON, F. D. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120
CAPRA, J. DONALD, VITETTA, ELLEN S., and KLEIN, JAN. Studies on the murine Ss protein. I. Purification, molecular weight, and subunit structure 664
CAUCHI, M. N., and DAWSON, K. B. Serum-mediated inhibition of graft-vs.-host reaction 248
CAULFIELD, JOHN P., and FARQUHAR, MARILYN G. The permeability of glomerular capillaries of aminonucleoside nephrotic rats to graded dextrans 61
CEROTTINI, JEAN-CHARLES. See MACDONALD, SORDAT, CEROTTINI, and BRUNNER 622
CHILLER, JACQUES M. See HABICHT, CHILLER, and WEIGLE 312
—. See SKIDMORE, MORRISON, CHILLER, and WEIGLE 1488
CHISARI, FRANCIS V., and EDGINGTON, THOMAS S. Lymphocyte E rosette inhibitory factor: a regulatory serum lipoprotein 1092
CHRISTMAN, JUDITH K., SILVERSTEIN, SAMUEL C., and ACS, GEORGE. Immunological analysis of plasminogen activators from normal and transformed hamster cells. Evidence that the plasminogen activators produced by SV40 virus-transformed hamster embryo cells and normal hamster lung cells are antigenically identical 419
CISAR, JOHN, KABAT, ELVIN A., DORNER, MARIANNE M., and LIAO, JERRY. Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran 435
CLARK, RICHARD A. F., GALLIN, JOHN I., and KAPLAN, ALLEN P. The selective eosinophil chemotactic activity of histamine 1462
CLARK, WILLIAM R. See NEDRUD, TOUTON, and CLARK 960
COCHRANE, CHARLES G. See ULEVITCH, COCHRANE, HENSON, MORRISON, and DOE 1570
COHEN, ALAN S. See BENSON, ALDO-BENSON, SHIRAHAMA, BOREL, and COHEN 236
COHEN, IRUN R. See ALTMAN and COHEN 790
COHN, ZANVIL A. See EDELSON, ZWIEBEL, and COHN 1150
—. See NOGUEIRA, BIANCO, and COHN 224

COLVIN, ROBERT, and DVORAK, HAROLD F. Fibrinogen/fibrin on the surface of macrophages: detection, distribution, binding requirements, and possible role in macrophage adherence phenomena 1377
CONE, JAMES L. See DICKLER, CONE, KUBICEK, and SACHS 796
COOPER, MAX D. See RAFF, OWEN, COOPER, LAWTON, MEGSON, and GATHINGS 1052
COUTINHO, ANTONIO, MÖLLER, GÖRAN, and GRONOWICZ, EVA. Genetical control of B-cell responses. IV. Inheritance of the unresponsiveness to lipopolysaccharides 253
CURRIE, G. A., and BASHAM, CONNIE. Activated macrophages release a factor which lyses malignant cells but not normal cells 1600

D

DAHL, LEWIS K., KNUDSEN, KNUD D., OHANIAN, EDWARD V., MUIRHEAD, MICHAEL, and TUTHILL, RALPH. Role of the gonads in hypertension-prone rats 748
DAVID, C. S. See TAUSSIG, MUNRO, CAMPBELL, DAVID, and STAINES 694
DAWSON, K. B. See CAUCHI and DAWSON 248
DAY, N. K. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495
DEBRÉ, PATRICE, KAPP, JUDITH A., and BENACERRAF, BARUJ. Genetic control of specific immune suppression. I. Experimental conditions for the stimulation of suppressor cells by the copolymer L-glutamic acid^{50}-L-tyrosine^{50} (GT) in nonresponder BALB/c mice 1436
—, —, DORF, MARTIN E., and —. Genetic control of specific immune suppression. II. *H-2*-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid^{50}-L-tyrosine^{50} (GT) 1447
D'EUSTACHIO, PETER, and EDELMAN, GERALD M. Frequency and avidity of specific antigen-binding cells in developing mice 1078
DEWEY, HENRY K. See PIGUET, DEWEY, and VASSALLI 1591
DICKLER, HOWARD B., CONE, JAMES L., KUBICEK, MARY T., and SACHS, DAVID H. Detection of non-H-2 antigen(s) which, like Ia antigens, are associated with the Fc receptor of B lymphocytes 796
—. See RYAN, ARBEIT, DICKLER, and HENKART 814
DIERICH, M. P., and REISFELD, R. A. C3-mediated cytoadherence. Formation of C3 receptor aggregates as prerequisite for cell attachment 242
DOE, WILLIAM F. See ULEVITCH, COCHRANE, HENSON, MORRISON, and DOE 1570
DORF, MARTIN E., BALNER, HANS, and BENACERRAF, BARUJ. Mapping of the immune response genes in the major histocompatibility complex of the rhesus monkey 673
—. See DEBRÉ, KAPP, DORF, and BENACERRAF 1447
—. See GERMAIN, DORF, and BENACERRAF 1023
DORNER, MARIANNE M. See CISAR, KABAT, DORNER, and LIAO 435
DUPONT, B. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495
DURKIN, HELEN G. See BASH, DURKIN, and WAKSMAN 1017
DVORAK, HAROLD F. See COLVIN and DVORAK 1377
DWYER, J. M., and KANTOR, F. S. In vivo suppression of delayed hypersensitivity: prolongation of desensitization in guinea pigs 588

E

EARDLEY, D. D., and GERSHON, RICHARD K. Feedback induction of suppressor T-cell activity 524
ECKNER, ROBERT J. Continuous replication of Friend virus complex (spleen focus-forming virus-lymphatic leukemia-inducing virus) in mouse embryo fibroblasts. Retention of leukemogenicity and loss of immunosuppressive properties 936
EDELMAN, GERALD M. See D'EUSTACHIO and EDELMAN 1078
EDELSON, PAUL J., ZWIEBEL, RENÉE, and COHN, ZANVIL A. The pinocytic rate of activated macrophages 1150
EDGINGTON, THOMAS S. See CHISARI and EDGINGTON 1092
EISEN, HERMAN N. See UNKELESS and EISEN 1520
ELKINS, WILLIAM, L. See SILVERS, ELKINS, and QUIMBY 1312
ERB, PETER, and FELDMANN, MARC. The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens 460
EVERLY, WILLIAM N. See LANCEFIELD, MCCARTY, and EVERLY 165

F

FARQUHAR, MARILYN G. See CAULFIELD and FARQUHAR 61
FEARON, DOUGLAS T., and AUSTEN, K. FRANK. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase 856
FELDMANN, MARC. See ERB and FELDMANN 460
FERREBEE, J. W. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120
FEWTRELL, CLARE. See LAWSON, FEWTRELL, GOMPERTS, and RAFF 391
FINAN, JANET B. See NOWELL, FINAN, and WILSON 230
FINKELMAN, FRED D., SMITH, ALLAN H., SCHER, IRWIN, and PAUL, WILLIAM E. Abnor-

mal ratio of membrane immunoglobulin classes in mice with an X-linked B-lymphocyte defect 1316
FISHELSON, ZVI. See BERKE and FISHELSON 1011
FLEISSNER, ERWIN. See TUNG, FLEISSNER, VITETTA, and BOYSE 518
FORMAN, JAMES. On the role of the *H-2* histocompatibility complex in determining the specificity of cytotoxic effector cells sensitized against syngeneic trinitrophenyl-modified targets 403
FOTINO, MARILENA. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495
FRANK, MICHAEL M. See GELFAND, FRANK, and GREEN 1029
FRAZIER, MARVIN. See VIOLA, FRAZIER, WHITE, BRODY, and SPIEGELMAN 483
FREEDMAN, HERBERT A., and LILLY, FRANK. Properties of cell lines derived from tumors induced by Friend virus in BALB/c and BALB/c-*H-2*^{b} mice 212
—, —, and STEEVES, RICHARD A. Antigenic properties of cultured tumor cell lines derived from spleens of Friend virus-infected BALB/c and BALB/c-*H-2*^{b} mice 1365
FRIDMAN, WOLF H. See GISLER and FRIDMAN 507
FU, S. M., STERN, R., KUNKEL, H. G., DUPONT, B., HANSEN, J. A., DAY, N. K., GOOD, R. A., JERSILD, C., and FOTINO, MARILENA. Mixed lymphocyte culture determinants and C2 deficiency: LD-7a associated with C2 deficiency in four families 495
—, WINCHESTER, R. J., and KUNKEL, H. G. The occurrence of the HL-B alloantigens on the cells of unclassified acute lymphoblastic leukemias 1334
FUCHS, SARA. See TARRAB-HAZDI, AHARONOV, ABRAMSKY, YAAR, and FUCHS 785
FUDENBERG, H. H. See LAMON, WHITTEN, LIDIN, and FUDENBERG 542
FUJITA, SHIGERU, LITWIN, STEPHEN D., and HARTMAN, NEIL. A glycoprotein associated with the membrane fraction of human B but not T lymphocytes 1416

G

GALANOS, CHRIS. See MELCHERS, BRAUN, and GALANOS 473
GALLIN, JOHN I. See CLARK, GALLIN, and KAPLAN 1462
GATHINGS, W. E. See RAFF, OWEN, COOPER, LAWTON, MEGSON, and GATHINGS 1052
GELFAND, MICHAEL C., FRANK, MICHAEL M., and GREEN, IRA. A receptor for the third component of complement in the human renal glomerulus 1029
GERMAIN, RONALD N., DORF, MARTIN E., and BENACERRAF, BARUJ. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor 1023
GERSHON, MICHAEL D. See GERSHON, ASKENASE, and GERSHON 732
GERSHON, RICHARD K., ASKENASE, PHILIP W., and GERSHON, MICHAEL D. Requirement for vasoactive amines for production of delayed-type hypersensitivity skin reactions 732
—. See EARDLEY and GERSHON 524
GEWURZ, HENRY. See OSMAND, MORTENSEN, SIEGEL, and GEWURZ 1065
—. See SIEGEL, OSMAND, WILSON, and GEWURZ 709
GISLER, ROLAND H., and FRIDMAN, WOLF H. Suppression of in vitro antibody synthesis by immunoglobulin-binding factor 507
GÖTZE, D. See WAGNER, GÖTZE, PTSCHELINZEW, and RÖLLINGHOFF 1477
GÖTZE, OTTO. See SCHREIBER, MEDICUS, GÖTZE, and MÜLLER-EBERHARD 760
GOMPERTS, BASTIEN. See LAWSON, FEWTRELL, GOMPERTS, and RAFF 391
GOOD, R. A. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495
GOODING, JAMES W., and WARNER, NOEL L. Transplantation behavior of A.TH and A.TL T-cell lymphomas in congenic resistant and hybrid strains 536
GORDON, ROBERT D., SIMPSON, ELIZABETH, and SAMELSON, LAWRENCE E. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice 1108
GORDON, SAIMON. See WERB and GORDON 346, 361
GOUD, THEO J. L. M., and VAN FURTH, RALPH. Proliferative characteristics of monoblasts grown in vitro 1200
—, SCHOTTE, CORINE, and —. Identification and characterization of the monoblast in mononuclear phagocyte colonies grown in vitro 1180
GOWANS, JAMES L. See PIERCE and GOWANS 1550
GRAHAM, RICHARD C., JR. See MAHMOUD, WARREN, and GRAHAM 560
GREEN, IRA. See BEN-SASSON, PAUL, SHEVACH, and GREEN 90
—. See GELFAND, FRANK, and GREEN 1029
GRIFFIN, FRANK M., JR., GRIFFIN, JOHANNA A., LEIDER, JUDITH E., and SILVERSTEIN, SAMUEL C. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane 1263
GRIFFIN, JOHANNA A. See GRIFFIN, GRIFFIN, LEIDER, and SILVERSTEIN 1263
GRONOWICZ, EVA. See COUTINHO, MÖLLER, and GRONOWICZ 253
GUTMAN, GEORGE A. See METCALF, NOSSAL, WARNER, MILLER, MANDEL, LAYTON, and GUTMAN 1534

H

HABICHT, G. S., CHILLER, JACQUES M., and WEIGLE, WILLIAM O. Termination of acquired and natural immunological tolerance with specific complexes 312

HANSEN, J. A. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495

HARRIS, S. See MANN, ABELSON, HARRIS, and AMOS 84

HART, P. D'ARCY. See ARMSTRONG and HART 1

HARTMAN, NEIL. See FUJITA, LITWIN, and HARTMAN 1416

HARTMANN, K.-U., and BOKISCH, V. A. Stimulation of murine B lymphocytes by isolated C3b 600

HAUPTFELD, VĚRA, and KLEIN, JAN. Molecular relationship between private and public *H-2* antigens as determined by antigen redistribution method 288

HAUSMAN, S. J., and BOSMA, M. J. Alteration of immunoglobulin phenotype in cell culture-adapted lines of two mouse plasmacytomas 998

HEBER-KATZ, ELLEN, and WILSON, DARCY B. Collaboration of allogeneic T and B lymphocytes in the primary antibody response to sheep erythrocytes in vitro 928

HENKART, PIERRE A. See RYAN, ARBEIT, DICKLER, and HENKART 814

HENSON, PETER M. See ULEVITCH, COCHRANE, HENSON, MORRISON, and DOE 1570

HEREMANS, JOSEPH F. See ANDRÉ, HEREMANS, VAERMAN, and CAMBIASO 1509

HERZENBERG, LEONARD A. See STOUT and HERZENBERG 611, 1041

HOFF, RODNEY. Killing in vitro of *Trypanosoma cruzi* by macrophages from mice immunized with *T. cruzi* or BCG, and absence of cross-immunity on challenge in vivo 299

HOFFMAN, HAROLD A. See STOCKERT, BOYSE, OBATA, IKEDA, SARKAR, and HOFFMAN 512

HUDSON, LESLIE. See VON BOEHMER, HUDSON, and SPRENT 989

—. See KRAMMER, HUDSON, and SPRENT 1403

HUMPHREY, WILLIAM, JR. See LIEBERMAN, POTTER, HUMPHREY, MUSHINSKI, and VRANA 106

HURST, MARY M., VOLANAKIS, JOHN E., STROUD, ROBERT M., and BENNETT, J. CLAUDE. Cl fixation and classical complement pathway activation by a fragment of the C $C\mu$ 4 domain of IgM 1322

I

IKEDA, HISAMI. See STOCKERT, BOYSE, OBATA, IKEDA, SARKAR, and HOFFMAN 512

J

JACOBSON, MARC W. See SONDEL, JACOBSON, and BACH 1606

JERSILD, C. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495

JOSEPH, BARRY S., and OLDSTONE, MICHAEL B. A. Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation 864

JOTEREAU, FRANCINE V. See LE DOUARIN and JOTEREAU 17

K

KABAT, ELVIN A. See CISAR, KABAT, DORNER, and LIAO 435

KAGNOFF, F. Functional characteristics of Peyer's patch cells. III. Carrier priming of T cells by antigen feeding 1425

KANTOR, F. S. See DWYER and KANTOR 588

KAPLAN, ALLEN P. See CLARK, GALLIN, and KAPLAN 1462

KAPP, JUDITH A., PIERCE, CARL W., and BENACERRAF, BARUJ. Genetic control of immune responses in vitro. VI. Experimental conditions for the development of helper T-cell activity specific for the terpolymer L-glutamic acid^{60}-L-alanine^{30}-L-tyrosine^{10} (GAT) in nonresponder mice 50

—. See DEBRÉ, KAPP, and BENACERRAF 1436

—. See DEBRÉ, KAPP, DORF, and BENACERRAF 1447

KAPPAS, A. See SASSA, SOLISH, LEVERE, and KAPPAS 722

KARNIELY, YUVAL. See TEITELBAUM, WEBB, RAUCH, KARNIELY, ARNON, and SELA 701

KATZ, DAVID H. See BULLOCK, KATZ, and BENACERRAF 261, 275

KIELY, JEANNE-MARIE. See CALDERON, KIELY, LEFKO, and UNANUE 151

KIUCHI, MASAHIRO. See OPELZ, KIUCHI, TAKASUGI, and TERASAKI 1327

KLEIN, JAN. See CAPRA, VITETTA, and KLEIN 664

—. See HAUPTFELD and KLEIN 288

KLINMAN, NORMAN R. See PIERCE and KLINMAN 1165

KNUDSEN, KNUD D. See DAHL, KNUDSEN, OHANIAN, MUIRHEAD, and TUTHILL 748

KONTIAINEN, SIRKKA, and ANDERSSON, LEIF C. Antigen-binding T cells as helper cells. Separation of helper cells by immune rosette formation 1035

KRAMMER, PETER H., HUDSON, LESLIE, and SPRENT, JONATHAN. Fc-receptors, Ia-antigens, and immunoglobulin on normal and activated mouse T lymphocytes 1403

KUBICEK, MARY T. See DICKLER, CONE, KUBICEK, and SACHS 796

KUHN, CHARLES. See LIN, KUHN, and KUO 877

KUNKEL, H. G. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495

—. See FU, WINCHESTER, and KUNKEL 1334

KUO, TSENG-TONG. See LIN, KUHN, and KUO 877

L

LAMON, E. W., WHITTEN, H. D., LIDIN, BODIL, and FUDENBERG, H. H. IgM-induced tumor cell cytotoxicity mediated by normal thymocytes 542

LANCEFIELD, REBECCA C., MCCARTY, MACLYN, and EVERLY, WILLIAM N. Multiple mouse-protective antibodies directed against Group B streptococci. Special reference to antibodies effective against protein antigens 165

LANE, DAVID P. See SILVER and LANE 1455

LAUF, P. K. Immunological and physiological characteristics of the rapid immune hemolysis of neuraminidase-treated sheep red cells produced by fresh guinea pig serum 974

LAWRENCE, H. S. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120

LAWSON, DURWARD, FEWTRELL, CLARE, GOMPERTS, BASTIEN, and RAFF, MARTIN C. Anti-immunoglobulin-induced histamine secretion by rat peritoneal mast cells studied by immunoferritin electron microscopy 391

LAWTON, ALEXANDER R., III. See RAFF, OWEN, COOPER, LAWTON, MEGSON, and GATHINGS 1052

LAYTON, JUDY E. See METCALF, NOSSAL, WARNER, MILLER, MANDEL, LAYTON, and GUTMAN 1534

LE DOUARIN, NICOLE M., and JOTEREAU, FRANCINE V. Tracing of cells of the avian thymus through embryonic life in interspecific chimeras 17

LEFKO, JANET L. See CALDERON, KIELY, LEFKO, and UNANUE 151

LEIDER, JUDITH E. See GRIFFIN, GRIFFIN, LEIDER, and SILVERSTEIN 1263

LEVERE, R. D. See SASSA, SOLISH, LEVERE, and KAPPAS 722

LIAO, JERRY. See CISAR, KABAT, DORNER, and LIAO 435

LIDIN, BODIL. See LAMON, WHITTEN, LIDIN, and FUDENBERG 542

LIEBERMAN, ROSE, POTTER, MICHAEL, HUMPHREY, WILLIAM, JR., MUSHINSKI, ELIZABETH B., and VRANA, MARK. Multiple individual and cross-specific idiotypes on 13 levan-binding myeloma proteins of BALB/c mice 106

LILLY, FRANK. See FREEDMAN and LILLY 212

—. See FREEDMAN, LILLY, and STEEVES 1365

LIN, HSIU-SAN, KUHN, CHARLES, and KUO, TSENG-TONG. Clonal growth of hamster free alveolar cells in soft agar 877

LINDER, EWERT, VAHERI, ANTTI, RUOSLAHTI, ERKKI, and WARTIOVAARA, JORMA. Distribution of fibroblast surface antigen in the developing chick embryo 41

LITWIN, STEPHEN D. See FUJITA, LITWIN, and HARTMAN 1416

LOEB, JOHN N., and YEUNG, LUCY L. Synthesis and degradation of ribosomal RNA in regenerating liver 575

LUCAS, SUSAN J. See SULLIVAN, BARRY, LUCAS, and ALBRECHT 773

M

MACDONALD, H. ROBSON, SORDAT, BERNARD, CEROTTINI, JEAN-CHARLES, and BRUNNER, K. THEODOR. Generation of cytotoxic T lymphocytes in vitro. IV. Functional activation of memory cells in the absence of DNA synthesis 622

MAHMOUD, ADEL A. F., WARREN, KENNETH S., and GRAHAM, RICHARD C., JR. Antieosinophil serum and the kinetics of eosinophilia in *Schistosomiasis mansoni* 560

—, —, and PETERS, PIERRE A. A role for the eosinophil in acquired resistance to *Schistosoma mansoni* inflection as determined by antieosinophil serum 805

MANDEL, THOMAS E. See METCALF, NOSSAL, WARNER, MILLER, MANDEL, LAYTON, and GUTMAN 1534

MANEJIAS, R. E. See RABINOVITCH, MANEJIAS, and NUSSENZWEIG 827

MANN, D. L., ABELSON, L., HARRIS, S., and AMOS, D. B. Detection of antigens specific for B-lymphoid cultured cell lines with human alloantisera 84

MCCARTY, MACLYN. See LANCEFIELD, MCCARTY, and EVERLY 165

MEDICUS, RUDOLF G. See SCHREIBER, MEDICUS, GÖTZE, and MÜLLER-EBERHARD 760

MEGSON, MARY. See RAFF, OWEN, COOPER, LAWTON, MEGSON, and GATHINGS 1052

MELCHERS, FRITZ, BRAUN, VOLKMAR, and GALANOS, CHRIS. The lipoprotein of the outer membrane of *Escherichia coli:* a B-lymphocyte mitogen 473

METCALF, DONALD, NOSSAL, G. J. V., WARNER, NOEL L., MILLER, JACQUES F. A. P., MANDEL, THOMAS E., LAYTON, JUDY E., and GUTMAN, GEORGE A. Growth of B-lymphocyte colonies in vitro 1534

MILLER, JACQUES F. A. P. See METCALF, NOSSAL, WARNER, MILLER, MANDEL, LAYTON, and GUTMAN 1534

MÖLLER, GÖRAN. See COUTINHO, MÖLLER, and GRONOWICZ 253

MOLLEN, N. See RAPAPORT, LAWRENCE, BACHVAROFF, CANNON, BLUMENSTOCK, MOLLEN, AYVAZIAN, and FERREBEE 120

MORRISON, DAVID C. See SKIDMORE, MORRISON, CHILLER, and WEIGLE 1488

—. See ULEVITCH, COCHRANE, HENSON, MORRISON, and DOE 1570

MORTENSEN, R. F. See OSMAND, MORTENSEN, SIEGEL, and GEWURZ 1065

MÜLLER-EBERHARD, HANS J. See SCHREIBER, MEDICUS, GÖTZE, and MÜLLER-EBERHARD 760

—. See SOBEL, BOKISCH, and MÜLLER-EBERHARD 139

MUIRHEAD, MICHAEL. See DAHL, KNUDSEN, OHANIAN, MUIRHEAD, and TUTHILL 748

MUNRO, A. J. See TAUSSIG, MUNRO, CAMPBELL, DAVID, and STAINES 694
MUSHINSKI, ELIZABETH B. See LIEBERMAN, POTTER, HUMPHREY, MUSHINSKI, and VRANA 106

N

NABHOLZ, M. See SPRENT, VON BOEHMER, and NABHOLZ 321
NATHAN, CARL F., and TERRY, WILLIAM D. Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages 887
NEDRUD, JOHN, TOUTON, MARY, and CLARK, WILLIAM R. The requirement for DNA synthesis and gene expression in the generation of cytotoxicity in vitro 960
NOGUEIRA, NADIA, BIANCO, CELSO, and COHN, ZANVIL. Studies on the selective lysis and purification of *Trypanosoma cruzi* 224
NOSSAL, G. J. V. See METCALF, NOSSAL, WARNER, MILLER, MANDEL, LAYTON, and GUTMAN 1534
NOWELL, PETER C., FINAN, JANET B., and WILSON, DARCY B. Proliferation in vivo of T lymphocytes reactive to histocompatibility alloantigens: a correction 230
NUSSENZWEIG, V. See RABINOVITCH, MANEJIAS, and NUSSENZWEIG 827

O

OBATA, YUICHI. See STOCKERT, BOYSE, OBATA, IKEDA, SARKAR, and HOFFMAN 512
OHANIAN, EDWARD V. See DAHL, KNUDSEN, OHANIAN, MUIRHEAD, and TUTHILL 748
OLDSTONE, MICHAEL B. A. See JOSEPH and OLDSTONE 864
OPELZ, GERHARD, KIUCHI, MASAHIRO, TAKASUGI, MITSUO, and TERASAKI, PAUL I. Autologous stimulation of human lymphocyte subpopulations 1327
OSMAND, ALEXANDER P., MORTENSEN, R. F., SIEGEL, JOAN, and GEWURZ, HENRY. Interactions of C-reactive protein with the complement system. III. Complement-dependent passive hemolysis initiated by CRP 1065
—. See SIEGEL, OSMAND, WILSON, and GEWURZ 709
OWEN, JOHN J. T. See RAFF, OWEN, COOPER, LAWTON, MEGSON, and GATHINGS 1052

P

PARKER, CHARLES W. See SHEARER and PARKER 1133
PAUL, WILLIAM E. See BEN-SASSON, PAUL, SHEVACH, and GREEN 90
—. See FINKELMAN, SMITH, SCHER, and PAUL 1316
—. See SCHER, STEINBERG, BERNING, and PAUL 637
PESANTI, EDWARD L., and AXLINE, STANTON G. Phagolysosome formation in normal and colchicine-treated macrophages 903
PETERS, PIERRE A. See MAHMOUD, WARREN, and PETERS 805
PIERCE, CARL W. See KAPP, PIERCE, and BENACERRAF 50
PIERCE, NATHANIEL F., and GOWANS, JAMES L. Cellular kinetics of the intestinal immune response to cholera toxoid in rats 1550
PIERCE, SUSAN K., and KLINMAN, NORMAN R. The allogeneic bisection of carrier-specific enhancement of monoclonal B-cell responses 1165
PIGUET, PIERRE F., DEWEY, HENRY K., and VASSALLI, PIERRE. Synergistic and suppressive interactions among mouse T lymphocytes in the response to phytohemagglutinin 1591
POLET, HERMAN, and SPIEKER-POLET, HELGA. Serum albumin is essential for in vitro growth of activated human lymphocytes 949
POTTER, MICHAEL. See LIEBERMAN, POTTER, HUMPHREY, MUSHINSKI, and VRANA 106
PTSCHELINZEW, L. See WAGNER GÖTZE, PTSCHELINZEW, and RÖLLINGHOFF 1477

Q

QUIMBY, FRED W. See SILVERS, ELKINS, and QUIMBY 1312

R

RABINOVITCH, M., MANEJIAS, R. E., and NUSSENZWEIG, V. Selective phagocytic paralysis induced by immobilized immune complexes 827
RAFF, MARTIN C., OWEN, JOHN J. T., COOPER, MAX D., LAWTON, ALEXANDER R., III, MEGSON, MARY, and GATHINGS, W. E. Differences in susceptibility of mature and immature mouse B lymphocytes to anti-immunoglobulin-induced immunoglobulin suppression in vitro. Possible implications for B-cell tolerance to self 1052
—. See LAWSON, FEWTRELL, GOMPERTS, and RAFF 391
RAPAPORT, F. T., LAWRENCE, H. S., BACHVAROFF, R., CANNON, F. D., BLUMENSTOCK, D., MOLLEN, N., AYVAZIAN, J. H., and FERREBEE, J. W. Histocompatibility studies in a closely bred colony of dogs. V. Mechanisms of cellular adaptation in long-term DL-A identical radiation chimeras 120
RAUCH, HELENE. See TEITELBAUM, WEBB, RAUCH, KARNIELY, ARNON, and SELA 701
RAUSEN, AARON R. See BHATNAGAR, ZABRISKIE, and RAUSEN 839
REINISCH, CAROL L. See BOREL, REINISCH, and SCHLOSSMAN 1254
REISFELD, R. A. See DIERICH and REISFELD 242
RIBLET, ROY. See TRENKNER and RIBLET 1121
RICH, ROBERT R. See RICH and RICH 1391

RICH, SUSAN SOLLIDAY, and RICH, ROBERT R. Regulatory mechanisms in cell-mediated immune response. II. A genetically restricted suppressor of mixed lymphocyte reactions released by alloantigen-activated spleen cells 1391
RÖLLINGHOFF, M. See WAGNER, GÖTZE, PTSCHELINZEW, and RÖLLINGHOFF 1477
ROSS, RUTH. See RUDDERS and ROSS 549
RUDDERS, RICHARD A., and ROSS, RUTH. Partial characterization of the shift from IgG to IgA synthesis in the clonal differentiation of human leukemic bone marrow-derived lymphocytes 549
RUOSLAHTI, ERKKI. See LINDER, VAHERI, RUOSLAHTI, and WARTIOVAARA 41
—. See VAHERI and RUOSLAHTI 530
RYAN, JOHN L., ARBEIT, ROBERT D., DICKLER, HOWARD B., and HENKART, PIERRE A. Inhibition of lymphocyte mitogenesis by immobilized antigen-antibody complexes 814

S

SACHS, DAVID H. See DICKLER, CONE, KUBICEK, and SACHS 796
SAMELSON, LAWRENCE E. See GORDON, SIMPSON and SAMELSON 1108
SARKAR, NURUL H. See STOCKERT, BOYSE, OBATA, IKEDA, SARKAR, and HOFFMAN 512
SASSA, S., SOLISH, G., LEVERE, R. D., and KAPPAS, A. Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait 722
SCHER, IRWIN, STEINBERG, ALFRED D., BERNING, ALICE K., and PAUL, WILLIAM E. X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect 637
—. See FINKELMAN, SMITH, SCHER, and PAUL 1316
SCHLOSSMAN, STUART F. See BOREL, REINISCH, and SCHLOSSMAN 1254
SCHMITT-VERHULST, ANNE-MARIE, and SHEARER, GENE M. Bifunctional major histocompatibility-linked genetic regulation of cell-mediated lympholysis to trinitrophenyl-modified autologous lymphocytes 914
SCHOTTE, CORINE. See GOUD, SCHOTTE, and VAN FURTH 1180
SCHREIBER, ROBERT D., MEDICUS, RUDOLF G., GÖTZE, OTTO, and MÜLLER-EBERHARD, HANS J. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor 760
SCOTT, JAMES R. See BEER, SCOTT, and BILLINGHAM 180
SEGAL, SHRAGA. See SILVERSTEIN, and SEGAL 802
SEHGAL, PRAVINKUMAR B., TAMM, IGOR, and VILČEK, JAN. Enhancement of human interferon production by neutral red and chloroquine: analysis of inhibition of protein degradation and macromolecular synthesis 1283
SELA, MICHAEL. See TEITELBAUM, WEBB, RAUCH, KARNIELY, ARNON, and SELA 701
SHEARER, GENE M. See SCHMITT-VERHULST and SHEARER 914
SHEARER, WILLIAM T., and PARKER, CHARLES W. Humoral immunostimulation. V. Selection of variant cell lines 1133
SHEVACH, ETHAN M. See BEN-SASSON, PAUL, SHEVACH, and GREEN 90
—. See BLOOM and SHEVACH 1306
SHIRAHAMA, TSURANOBU. See BENSON, ALDO-BENSON, SHIRAHAMA, BOREL, and COHEN 236
SIEGEL, JOAN, OSMAND, ALEXANDER P., WILSON, MICHAEL, F., and GEWURZ, HENRY. Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations 709
—. See OSMAND, MORTENSEN, SIEGEL, and GEWURZ 1065
SILVER, DONALD M., and LANE, DAVID P. Dominant nonresponsiveness in the induction of autoimmunity to liver-specific F antigen 1455
SILVERS, WILLYS K., ELKINS, WILLIAM L., and QUIMBY, FRED W. Cellular basis of tolerance in neonatally induced mouse chimeras 1312
SILVERSTEIN, ARTHUR M., and SEGAL, SHRAGA. The ontogeny of antigen-specific T cells 802
SILVERSTEIN, SAMUEL C. See CHRISTMAN, SILVERSTEIN, and ACS 419
—. See GRIFFIN, GRIFFIN, LEIDER, and SILVERSTEIN 1263
SIMPSON, ELIZABETH. See GORDON, SIMPSON, and SAMELSON, 1108
SKIDMORE, BARRY J., MORRISON, DAVID C., CHILLER, JACQUES M., and WEIGLE, WILLIAM O. Immunologic properties of bacterial lipopolysaccharide (LPS). II. The unresponsiveness of C3H/HeJ mouse spleen cells to LPS-induced mitogenesis is dependent on the method used to extract LPS 1488
SMITH, ALLAN H. See FINKELMAN, SMITH, SCHER, and PAUL 1316
SOBEL, A. T., BOKISCH, V. A., and MÜLLER-EBERHARD, H. J. C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum 139
SOLISH, G. See SASSA, SOLISH, LEVERE, and KAPPAS 722
SONDEL, PAUL M., and BACH, PETER H. Recognitive specificity of human cytotoxic T lymphocytes. I. Antigen-specific inihibition of human cell-mediated lympholysis 1339
—, JACOBSON, MARC W., and BACH, FRITZ H. Pre-emption of human cell-mediated lympholysis by a suppressive mechanism activated

in mixed lymphocyte cultures 1606
SORDAT, BERNARD. See MACDONALD, SORDAT, CEROTTINI, and BRUNNER 622
SPIEGELMAN, SOL. See VIOLA, FRAZIER, WHITE, BRODY, and SPIEGELMAN 483
SPIEKER-POLET, HELGA. See POLET and SPIEKER-POLET 949
SPRENT, J., VON BOEHMER, H., and NABHOLZ, M. Association of immunity and tolerance to host *H-2* determinants in irradiated F_1 hybrid mice reconstituted with bone marrow cells from one parental strain 321
—. See KRAMMER, HUDSON, and SPRENT 1403
—. See VON BOEHMER, HUDSON, and SPRENT 989
STAINES, N. A. See TAUSSIG, MUNRO, CAMPBELL, DAVID, and STAINES 694
STEEVES, RICHARD A. See FREEDMAN, LILLY, and STEEVES 1365
STEINBERG, ALFRED D. See SCHER, STEINBERG, BERNING, and PAUL 637
STERN, R. See FU, STERN, KUNKEL, DUPONT, HANSEN, DAY, GOOD, JERSILD, and FOTINO 495
STOCKERT, ELISABETH, BOYSE, EDWARD A., OBATA, YUICHI, IKEDA, HISAMI, SARKAR, NURUL H., and HOFFMAN, HAROLD A. New mutant and congenic mouse stocks expressing the murine leukemia virus-associated thymocyte surface antigen G_{IX} 512
STOUT, ROBERT D., and HERZENBERG, LEONARD A. The Fc receptor on thymus-derived lymphocytes. I. Detection of a subpopulation of murine T lymphocytes bearing the Fc receptor 611
— and —. II. Mitogen responsiveness of T lymphocytes bearing the Fc receptor 1041
STROUD, ROBERT M. See HURST, VOLANAKIS, STROUD, and BENNETT 1322
SULLIVAN, JOHN L., BARRY, DAVID W., LUCAS, SUSAN J., and ALBRECHT, PAUL. Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes 773

T

TADA, TOMIO. See TAKEMORI and TADA 1241
TAKASUGI, MITSUO. See OPELZ, KIUCHI, TAKASUGI, and TERASAKI 1327
TAKEMORI, TOSHITADA, and TADA, TOMIO. Properties of antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. I. In vivo activity and immunochemical characterizations 1241
TAMM, IGO. See SEHGAL, TAMM, and VILČEK 1283
TARRAB-HAZDI, REBECA, AHARONOV, AHARON, ABRAMSKY, ODED, YAAR, ISRAEL, and FUCHS, SARA. Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs 785
TAUSSIG, M. J., MUNRO, A. J., CAMPBELL, ROSALIE, DAVID, C. S., and STAINES, N. A. Antigen-specific T-cell factor in cell cooperation. Mapping within the *I* region of the *H-2* complex and ability to cooperate across allogeneic barriers 694
TEITELBAUM, DVORA, WEBB, CYNTHIA, RAUCH, HELENE, KARNIELY, YUVAL, ARNON, RUTH, and SELA, MICHAEL. Inverse relationship between net electric charge on the antigen and that on the sensitized cell in immune cellular response: demonstration with basic encephalitogen of the brain 701
TERASAKI, PAUL I. See OPELZ, KIUCHI, TAKASUGI, and TERASAKI 1327
TERRY, WILLIAM D. See NATHAN and TERRY 887
TOUTON, MARY. See NEDRUD, TOUTON, and CLARK 960
TRENKNER, EKKHART, and RIBLET, ROY. Induction of antiphosphorylcholine antibody formation by anti-idiotypic antibodies 1121
TUNG, JWU-SHENG, FLEISSNER, ERWIN, VITETTA, ELLEN S., and BOYSE, EDWARD A. Expression of murine leukemia virus envelope glycoprotein gp69/71 on mouse thymocytes. Evidence for two structural variants distinguished by presence vs. absence of G_{IX} antigen 518
TUTHILL, RALPH. See DAHL, KNUDSEN, OHANIAN, MUIRHEAD, and TUTHILL 748

U

ULEVITCH, RICHARD J., COCHRANE, CHARLES G., HENSON, PETER M., MORRISON, DAVID C., and DOE, WILLIAM F. Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. Role of complement 1570
UNANUE, EMIL R. See CALDERON, KIELY, LEFKO, and UNANUE 151
UNKELESS, JAY C., and EISEN, HERMAN N. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages 1520

V

VAERMAN, JEAN PIERRE. See ANDRÉ, HEREMANS, VAERMAN, and CAMBIASO 1509
VAHERI, ANTTI, and RUOSLAHTI, ERKKI. Fibroblast surface antigen produced but not retained by virus-transformed human cells 530
—. See LINDER, VAHERI, RUOSLAHTI, and WARTIOVAARA 41
VASSALLI, PIERRE. See PIGUET, DEWEY, and VASSALLI 1591
VILČEK, JAN. See SEHGAL, TAMM, and VILČEK 1283
VIOLA, MICHAEL V., FRAZIER, MARVIN, WHITE, LON, BRODY, JACOB, and SPIEGELMAN, SOL. RNA-instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains

from Guamanian patients 483
VITETTA, ELLEN S. See CAPRA, VITETTA, and KLEIN 664
VOLANAKIS, JOHN E. See HURST, VOLANAKIS, STROUD, and BENNETT 1322
—. See TUNG, FLEISSNER, VITETTA, and BOYSE 518
VAN FURTH, RALPH. See GOUD and VAN FURTH 1200
—. See GOUD, SCHOTTE, and VAN FURTH 1180
VON BOEHMER, H., HUDSON, LESLIE, and SPRENT, JONATHAN. Collaboration of histoincompatible T and B lymphocytes using cells from tetraparental bone marrow chimeras 989
—. See SPRENT, VON BOEHMER, and NABHOLZ 321
VRANA, MARK. See LIEBERMAN, POTTER, HUMPHREY, MUSHINSKI, and VRANA 106

W

WAGNER, H., GÖTZE, D., PTSCHELINZEW, L., and RÖLLINGHOFF, M. Induction of cytotoxic T lymphocytes against *I*-region-coded determinants: in vitro evidence for a third histocompatibility locus in the mouse 1477
WAKSMAN, BYRON H. See BASH, DURKIN, and WAKSMAN 1017
WALKER, DONALD G. Control of bone resorption by hematopoietic tissue. The induction and reversal of congenital osteopetrosis in mice through the use of bone marrow and splenic transplants 651
WARNER, NOEL L. See GOODING and WARNER 536
—. See METCALF, NOSSAL, WARNER, MILLER, MANDEL, LAYTON, and GUTMAN 1534
WARREN, KENNETH S. See MAHMOUD, WARREN, and GRAHAM 560
—. See MAHMOUD, WARREN, and PETERS 805
WARTIOVAARA, JORMA. See LINDER, VAHERI, RUOSLAHTI, and WARTIOVAARA 41
WEBB, CYNTHIA. See TEITELBAUM, WEBB, RAUCH, KARNIELY, ARNON, and SELA 701
WEIGLE, WILLIAM O. See HABICHT, CHILLER, and WEIGLE 312
—. See SKIDMORE, MORRISON, CHILLER, and WEIGLE 1488
WERB, ZENA, and GORDON, SAIMON. Elastase secretion by stimulated macrophages. Characterization and regulation 361
— and —. Secretion of a specific collagenase by stimulated macrophages 346
WHITE, LON. See VIOLA, FRAZIER, WHITE, BRODY, and SPIEGELMAN 483
WHITTEN, H. D. See LAMON, WHITTEN, LIDIN, and FUDENBERG 542
WIGZELL, HANS. See BINZ and WIGZELL 197, 1218, 1231
WILSON, DARCY B. See HEBER-KATZ and WILSON 928
—. See NOWELL, FINAN, and WILSON 230
WILSON, MICHAEL F. See SIEGEL, OSMAND, WILSON, and GEWURZ 709
WINCHESTER, R. J. See FU, WINCHESTER, and KUNKEL 1334
WU, SHAOKEE, BACH, FRITZ H., and AUERBACH, ROBERT. Cell-mediated immunity: differential maturation of mixed leukocyte reaction and cell-mediated lympholysis 1301

Y

YAAR, ISRAEL. See TARRAB-HAZDI, AHARONOV, ABRAMSKY, YAAR, and FUCHS 785
YEUNG, LUCY L. See LOEB and YEUNG 575

Z

ZABRISKIE, JOHN B. See BHATNAGAR, ZABRISKIE, and RAUSEN 839
ZWERNER, ROBERT K., and ACTON, RONALD T. Growth properties and alloantigenic expression of murine lymphoblastoid cell lines 378
ZWIEBEL, RENÉE. See EDELSON, ZWIEBEL, and COHN 1150

INDEX TO SUBJECTS

A

Activators, plasminogen, immunological analysis from normal and transformed hamster cells, 419
Adherence phenomena, macrophage, role of surface fibrinogen/fibrin, 1377
Alanine-glutamic acid-tyrosine-specific helper T-cell function, genetic control of immune response, 50
Albumin, serum, and lymphocyte growth, 949
Alloantigen activation of spleen cells, suppression of mixed lymphocyte reactions, 1391
—, histocompatibility, T lymphocytes reactive to, 230
—, HL-B, cells of unclassified acute lymphoblastic leukemias, 1334
—, murine lymphoblastoid cell lines, 378
—, similar idiotypes on immunoglobulins and T-cell receptors with shared specificity for, 197
Alloantisera, human, detection of antigens specific for B-lymphoid cell lines, 84
— inhibition of T lymphocyte tumor-specific lysis, 1023
Allogeneic bisection, carrier-specific enhancement of monoclonal B-cell responses, 1165
Allotype suppression, components of antiallotype serum active in release from, 332
Alveolar cells, free, hamster, clonal growth in soft agar, 877
Amines, vasoactive, delayed-type hypersensitivity skin reactions, 732
Aminonucleoside nephrosis, glomerular capillary permeability to graded dextrans, 61
Amniotic cells, and fibroblasts, human, gene defect of acute intermittent porphyria, prenatal diagnosis, 722
Amyloidosis, genetic control of polyclonal B-cell activator induction, 1564
—, suppression of antibody response by serum factor, 236
Antiallotype serum components active in release from allotype suppression, 332
Antibody, antiphosphorylcholine, induction of formation by anti-idiotypic antibodies, 1121
—, mouse-protective, against Group B streptococci, 165
— response, primary, cooperation of T and B lymphocytes, 928
— response regulation, antigen-specific suppressive T-cell factor, 1241
— response, suppression by serum factor, amyloidosis, 236
Antibody synthesis, suppression by immunoglobulin-binding factor, 507
Antibody-antigen complex, immobilized, inhibition of lymphocyte mitogenesis, 814
— complexes, induction of immunological tolerance by antigen feeding, 1509
Antieosinophil serum, eosinophil kinetics in *Schistosomiasis mansoni*, 560
Antigen activation of T lymphocytes, phytohemagglutinin response, 1017
— binding cells, frequency and avidity of, developing mice, 1078
— determinants in dextran, binding properties of immunoglobulin combining sites, 435
—, F, liver-specific, dominant nonresponsiveness in induction of autoimmunity, 1455
— feeding, carrier priming of T cells, Peyer's patch cells, 1425
— feeding, induction of immunological tolerance, antigen-antibody complexes, 1509
—, fibroblast surface, distribution of, chick embryo, 41
—, fibroblast surface, virus-transformed human cells, 530
— G_{IX}, murine leukemia virus envelope glycoprotein on thymocytes, 518
— G_{IX}, murine leukemia virus-associated thymocyte surface, 512
—, male-specific, cell-mediated immune responses to, 1108
— modulation, suppression of immune injury, measles virus infection, 864
— redistribution method, molecular relationship between private and public *H-2* antigens, 288
— and sensitized cell net electric charge, immune response, brain encephalitogen, 701
—, small molecular weight, T lymphocyte response, T-T cell interactions, suppression vs. enhancement, 275
—, small molecular weight, T lymphocyte tolerance to azobenzenearsonate conjugate, 261
—, specific factor, T-cell, mapping of *I* region of *H-2* complex, 694
—, specific, T cells, ontogeny of, 802
—, surface, cultured tumor cell lines derived from Friend virus-infected spleen, 1365
—, T-cell binding, separation of helper cells by immune rosette formation, 1035
Antigens, cell surface, target cells bound to cytotoxic T lymphocytes, 1011
—, Ia, Fc receptors, and immunoglobulin, T lymphocytes, 1403
—, minor histocompatibility, susceptibility of cytotoxic T cells, 1349

Antigens, non-*H2*, association with Fc receptor of B lymphocytes, 796
—, protein, mouse-protective antibodies against Group B streptococci, 165
—, soluble, genetic control of macrophage and T-cell interaction for helper cell induction, 460
— specific for B-lymphoid cell lines, detection with human alloantisera, 84
Antigen-antibody complex, immobilized, inhibition of lymphocyte mitogenesis, 814
Antigen-specific inhibition, cell-mediated lympholysis, recognitive specificity of human cytotoxic T lymphocytes, 1339
— suppressive T-cell factor, regulation of antibody response, 1241
— T lymphocytes, selection and culture of, 90
Anti-immunoglobulin-induced histamine secretion, 391
Autoimmunity, liver-specific F antigen, dominant nonresponsiveness in induction of, 1455
Avidity, specific antigen-binding cells, developing mice, 1078
Azobenzenearsonate conjugate, T lymphocyte tolerance to, 261

B

B lymphocyte clonal differentiation, human leukemia, shift from IgG to IgA synthesis, 549
— lymphocyte colonies, in vitro growth, 1534
— lymphocyte Fc receptor, association of non-*H-2* antigens, 796
— lymphocyte, human, glycoprotein and membrane association, 1416
— lymphocyte immune defect, X-linked, 637
— lymphocyte mitogen, *Escherichia coli* outer membrane lipoprotein, 473
— lymphocyte, murine, stimulation by isolated C3b, 600
— lymphocyte, susceptibility to anti-immunoglobulin-induced immunoglobulin suppression, 1052
— lymphocyte, X-linked defect, abnormal ratio of membrane immunoglobulin, 1316
B- and T-cells, hapten-specific carrier-determined tolerance, 1254
Bacille Calmette-Guérin-activated macrophages, stimulation of lymphoma growth, 887
Bacilli, virulent tubercle, phagosome-lysosome interactions in macrophages infected with, 1
B-cells activator, polyclonal, induction of amyloidosis, genetic control, 1564
—, cooperation with T lymphocytes in primary antibody response, 928
—, cooperation with T lymphocytes, tetraparental bone marrow chimeras, 989
— monoclonal responses, carrier-specific enhancement of, allogeneic bisection, 1165
B-cells unresponsiveness to lipopolysaccharides, genetic control, 253
B-lymphoid cell line antigens, detection with human alloantisera, 84
Binding, fibrinogen/fibrin, macrophage surface, 1377
— properties, immunoglobulin combining sites, antigenic determinants in dextran, 435
Bone marrow transplant, control of congenital osteopetrosis, 651
— resorption, control by hematopoietic tissue, bone marrow and splenic transplants in congenital osteopetrosis, 651
Brain encephalitogen, net electric charge on antigen and sensitized cell in immune response, 701
Brains, Guamanian patients with amyotrophic lateral sclerosis and Parkinsonism-dementia, RNA-instructed DNA polymerase, 483

C

Capillary, glomerular, aminonucleoside nephrosis, permeability to graded dextrans, 61
Carrier priming of T-cells by antigen feeding, Peyer's patch cells, 1425
Carrier-specific enhancement of monoclonal B-cell responses, allogeneic bisection, 1165
Cell attachment, C3 receptor aggregates, 242
—, B-, activators, polyclonal, induction of amyloidosis, genetic control, 1564
—, B-, unresponsiveness to lipopolysaccharides, genetic control, 253
— components, thymus, avian embryo, histogenesis of, 17
— line variants, humoral immunostimulation, 1133
— lines, B-lymphoid, detection of specific antigens with human alloantisera, 84
— lines derived from Friend virus-induced tumors, 212
— lines, tumor, Friend virus-infected spleen, surface antigens, 1365
—, sensitized, and antigen net electric charge, immune response, brain encephalitogen, 701
—, target, binding to cytotoxic T lymphocytes, cell surface antigens, 1011
Cell-mediated immune response to male-specific antigen, 1108
— immune response, suppression of mixed lymphocyte reactions by alloantigen-activated spleen cells, 1391
— lympholysis, antigen-specific inhibition, recognitive specificity of human cytotoxic T lymphocytes, 1339
— lympholysis, human, suppression in mixed lymphocyte culture, 1606
— lympholysis, and mixed leukocyte reaction, 1301
Cells, amniotic, and fibroblasts, human, gene

defect of acute intermittent porphyria, prenatal diagnosis, 722
—, antigen-binding, frequency and avidity of, developing mice, 1078
—, B-, susceptibility to anti-immunoglobulin-induced immunoglobulin suppression, 1052
—, B- and T-, hapten-specific carrier-determined tolerance, 1254
—, B and T lymphocytes, histoincompatibility, tetraparental bone marrow chimeras, 989
—, B and T lymphocytes, primary antibody response, 928
—, B and T lymphocytes, shared idiotypes, fractionation of specific immunocompetent T lymphocytes, 1231
—, B and T lymphocytes, shared idiotypes, frequency and characteristics of, 1218
—, blood, red. *See* Erythrocytes.
—, bone marrow, radiation chimeras, association of immunity and tolerance, 321
—, cytotoxic effector, role of *H-2* histocompatibility complex in determination of specificity of, 403
—, free alveolar, hamster, clonal growth in soft agar, 877
—, hamster, normal and transformed, immunological analysis of plasminogen activators, 419
—, human lymphocytes and monocytes, measles infection, 773
—, human virus-transformed, fibroblast surface antigen, 530
—, lymph node, passive transfer of autoimmune myasthenia, 785
—, malignant, lysis by macrophage factor, 1600
—, memory, cytotoxic T lymphocytes, functional activation of in absence of DNA synthesis, 622
—, murine lymphoblastoid, alloantigenic expression, 378
—, peritoneal mast, anti-immunoglobulin-induced histamine secretion, 391
—, Peyer's patch, carrier priming of T-cells by antigen feeding, 1425
—, spleen, alloantigen-activated, suppression of mixed lymphocyte reactions, 1391
—, spleen, mouse, lipopolysaccharide-induced mitogenesis, 1488
—, suppressor, stimulation by copolymer glutamic acid-tyrosine, 1436
—, T-, antigen-specific, ontogeny of, 802
—, T-, antigen-specific suppressive factor, regulation of antibody response, 1241
—, T-, cytotoxic, histocompatibility against minor antigens, 1349
—, T-, factor, antigen-specific, mapping of *I* region of *H-2* complex, 694
—, T-, helper activity, glutamic acid-alanine-tyrosine-specific, genetic control of immune response, 50
—, T-, helper, genetic control of macrophage interaction, 460
Cells, T lymphocytes antigen-specific, selection and culture of, 90
—, T-, lymphomas, transplantation behavior, 536
—, T-, and migration inhibitory factor, 1306
—, T-, receptors, and immunoglobulins with specificity for same alloantigens, shared idiotypes on, 197
—, T-, response to small molecular weight antigen, tolerance to azobenzenearsonate conjugate, 261
—, T-, suppressor activity, feedback induction, 524
—, T-T interactions, response to small molecular weight antigen, suppression vs. enhancement, 275
—, tumor, IgM-induced cytotoxicity, normal thymocytes, 542
—, unclassified acute lymphoblastic leukemias, HL-B alloantigens, 1334
Cellular adaptation in DL-A radiation chimeras, 120
— basis of tolerance, neonatally-induced mouse chimeras, 1312
— kinetics, intestinal immune response to cholera toxoid, 1462
Chemotaxis, eosinophil histamine, 1462
Chimeras, interspecific, histogenesis of thymus cell components, avian embryo, 17
—, neonatally-induced mouse, cellular basis of tolerance, 1312
—, radiation, association of immunity and tolerance, 321
—, radiation, cellular adaptation, histocompatibility studies, 120
—, tetraparental bone marrow, collaboration of histoincompatible T and B lymphocytes, 989
Chloroquine and neutral red enhancement of human interferon production, inhibition of protein degradation and macromolecular synthesis, 1283
Cholera toxoid, cellular kinetics of intestinal immune response to, 1550
Clonal differentiation, human leukemic B lymphocytes, shift from IgG to IgA synthesis, 549
— growth, hamster free alveolar cells in soft agar, 877
—, mono-, B-cell responses, carrier-specific enhancement of, allogeneic bisection, 1165
—, poly-, B-cell activator induction of amyloidosis, genetic control, 1564
Clq deviation test, detection of immune complexes, IgG aggregates, bacterial products in human serum, 139
Coagulation, disseminated intravascular, and lipopolysaccharide-induced hypotension, mediation systems, 1570
Colchicine-treated macrophages, phagolysosome formation, 903
Collagenase, macrophage secretion of, 346
Complement activation by Cμ4 fragment of

IgM, $C\bar{1}$ fixation, 1322
— C2 deficiency, mixed lymphocyte culture determinants, 495
— C3 convertases, properdin- and nephritic factor-dependent, 760
— C3 receptor aggregates, cell attachment, 242
— C3b, isolated, stimulation of B lymphocytes, 600
— C3b, properdin binding, stabilization of C3b-dependent C3 convertase, 856
— and passive hemolysis, initiation by C-reactive protein, 1065
— system interactions with C-reactive protein, role of polycations, 709
—, third component receptor, human renal glomerulus, 1029
Complex, antigen-antibody, immobilized, inhibition of lymphocyte mitogenesis, 814
—, antigen-antibody, induction of immunological tolerance by antigen feeding, 1509
—, antigen-antibody, termination of acquired and natural immunological tolerance, 312
—, *H-2* histocompatibility, role in syngeneic cell-mediated lympholysis, 403
—, immune immobilized, induction of selective phagocytic paralysis, 827
—, major histocompatibility, susceptibility of cytotoxic T cells against minor antigens, 1349
Convertase, C3b-dependent C3, stabilization of, properdin-C3b binding, 856
Convertases, C3, properdin- and nephritic factor-dependent, 760
Copolymer glutamic acid-tyrosine, *H-2*-linked dominant genetic control of immune suppression, 1447
— glutamic acid-tyrosine, stimulation of suppressor cells, 1436
C-reactive protein initiation of complement-dependent passive hemolysis, 1065
— protein interactions with complement system, role of polycations, 709
Cross-immunity in vivo, absence of, in vitro macrophage killing of *Trypanosoma cruzi*, 299
Cytotoxicity, DNA synthesis and gene expression, 960
—, IgM-induced tumor cell, normal thymocytes, 542

D

Deoxyribonucleic acid polymerase, RNA-instructed, brains from Guamanian patients, 483
— acid synthesis, functional activation of cytotoxic T lymphocytes in absence of, 622
— acid synthesis and gene expression, generation of cytotoxicity, 960
Desensitization prolongation, in vivo suppression of delayed hypersensitivity, 588
Dextran, antigenic determinants, binding properties of immunoglobulin combining sites, 435
Dextrans, graded, permeability of glomerular capillaries to, aminonucleoside nephrosis, 61

E

Elastase, macrophage secretion of, 361
Electric charge, net, antigen and sensitized cell, immune response, brain encephalitogen, 701
Embryo, avian, histogenesis of thymus cell components, 17
—, chick, fibroblast surface antigen distribution, 41
Encephalitogen, brain, net electric charge on antigen and sensitized cell in immune response, 701
Envelope glycoprotein, leukemia virus, mouse thymocytes, G_{IX} antigen, 518
Eosinophil chemotactic activity of histamine, 1462
— kinetics, antieosinophil serum, *Schistosomiasis mansoni*, 560
— role in acquired resistance to *Schistosoma mansoni* infection, 805
Erythrocytes, neuraminidase-treated, immune hemolysis of, 974
Escherichia coli outer membrane lipoprotein, B-lymphocyte mitogen, 473

F

F antigen, liver-specific, dominant nonresponsiveness in induction of autoimmunity, 1455
Factor, immunoglobulin-binding, suppression of antibody synthesis, 507
Fc receptors of B lymphocytes, association of non-*H-2* antigens, 796
— receptors, Ia-antigens, and immunoglobulin, T lymphocytes, 1403
— receptors, macrophages, binding of monomeric immunoglobulins, 1520
— receptors, murine T lymphocytes, 611
— receptors on T lymphocytes, mitogen responsiveness, 1041
Feedback induction, suppressor T-cell activity, 524
Fetoplacental weight and litter size, histocompatibility and maternal immunological status, 180
Fibrinogen/fibrin, macrophage surface, role in adherence phenomena, 1377
Fibroblasts and amniotic cells, human, gene defect of acute intermittent porphyria, prenatal diagnosis, 722
—, chick embryo, distribution of surface antigen, 41
—, mouse embryo, continuous replication of Friend virus complex, retention of leukemogenicity and loss of immunosuppression, 936

Fibroblasts and amniotic cells, surface antigen, virus-transformed human cells, 530
Fibrosarcoma, methylcholanthrene-induced, cellular immune response to, 839
Fixation, $C\bar{1}$, complement activation by $C\mu 4$ fragment of IgM, 1322
Friend virus, cell lines derived from tumors induced by, 212
— virus complex, continuous replication of in mouse embryo fibroblasts, retention of leukemogenicity and loss of immunosuppression, 936
— virus, infected spleen, surface antigens of cultured tumor cell lines from, 1365

G

G_{IX} antigen, murine leukemia virus-associated thymocyte surface, 512
— antigen, murine leukemia virus envelope glycoprotein on thymocytes, 518
Gene defect, acute intermittent porphyria, cultured human fibroblasts and amniotic cells, prenatal diagnosis, 722
— expression and DNA synthesis, generation of cytotoxicity, 960
— mapping, immune response, histocompatibility complex, rhesus monkey, 673
Genetic control, B-cell unresponsiveness to lipopolysaccharides, 253
— control, histocompatibility-linked, cell-mediated lympholysis to trinitrophenyl-modified lymphocytes, 914
— control of immune response, development of glutamic acid-alanine-tyrosine-specific helper T-cell activity, 50
— control, immune suppression, *H-2*-linked dominant control by copolymer glutamic acid-tyrosine, 1447
— control, immune suppression, stimulation of suppressor cells by copolymer glutamic acid-tyrosine, 1436
— control, macrophage and T-cell interaction for helper cell induction, 460
— control, polyclonal B-cell activator induction of amyloidosis, 1564
Glomerulus, aminonucleoside nephrosis, capillary permeability to graded dextrans, 61
—, renal, human, receptor for complement third component, 1029
Glutamic acid-alanine-tyrosine-specific helper T-cell function, genetic control of immune response, 50
Glutamic acid-tyrosine copolymer, *H-2*-linked dominant genetic control of immune suppression, 1447
— copolymer, stimulation of suppressor cells, 1436
Glycoprotein, association with human B lymphocyte membrane, 1416
—, leukemia virus envelope, mouse thymocytes, G_{IX} antigen, 518
Gonads, role in hypertension, 748
Graft-vs.-host reaction, serum-mediated inhibition, 248
Guam, patients with amyotrophic lateral sclerosis and Parkinsonism-dementia, brain RNA-instructed DNA polymerase, 483

H

H-2 antigens, public and private, molecular relationship determined by antigen redistribution method, 288
— complex, mapping of *I* region, antigen-specific T-cell factor, 694
— dominant genetic control of immune suppression by copolymer glutamic acid-tyrosine, 1447
— histocompatibility complex, role in syngeneic cell-mediated lympholysis, 403
— host determinants, association of immunity and tolerance in radiation chimeras, 321
Hapten-specific carrier-determined tolerance, T and B cells, 1254
Hematopoietic tissue, control of bone resorption, bone marrow and splenic transplants in congenital osteopetrosis, 651
Hemolysis, immune, and neuraminidase treatment, 974
—, passive, complement-dependent, initiation by C-reactive protein, 1065
Histamine, eosinophil, chemotactic activity, 1462
— secretion, anti-immunoglobulin-induced, 391
Histocompatibility alloantigens, T lymphocytes reactive to, 230
—, cellular adaptation in DL-A radiation chimeras, 120
— complex, *H-2*, role in syngeneic cell-mediated lympholysis, 403
— complex, major, susceptibility of cytotoxic T cells against minor antigens, 1349
— complex, mapping of immune response genes, rhesus monkey, 673
—, fetoplacental weight and litter size, 180
—, genetic control of cell-mediated lympholysis to trinitrophenyl-modified lymphocytes, 914
—, third locus, cytotoxic T lymphocytes, I-region-coded determinants, 1477
Histoincompatibility, collaboration of B and T lymphocytes, tetraparental bone marrow chimeras, 989
Host-vs.-graft reaction, serum-mediated inhibition, 248
Humoral immunostimulation, variant cell lines, 1133
Hydrocortisone, sensitivity of cytotoxic T lymphocytes, 790
Hypersensitivity, delayed, in vivo suppression of, 588
— skin reactions, delayed-type, role of vasoactive amines, 732
Hypertension, role of gonads, 748

Hypotension, lipopolysaccharide induction, and disseminated intravascular coagulation, mediation systems, 1570

I

Idiotypes, anti-, antibodies, induction of anti-phosphorylcholine antibody formation, 1121
—, individual and cross-specific, levan-binding myeloma proteins, 106
—, shared, B and T lymphocytes, fractionation of specific immunocompetent T lymphocytes, 1231
—, shared, B and T lymphocytes, frequency and characteristics of, 1218
—, shared, B and T lymphocytes with specificity for same alloantigens, 197
Immune complexes, IgG aggregates, and bacterial products in human serum, Clq deviation test, 139
— defect, B lymphocyte, X-linked, 637
— hemolysis and neuraminidase treatment, 974
— response, cell-mediated, to male-specific antigen, 1108
— response, cell-mediated, suppression of mixed lymphocyte reactions by alloantigen-activated spleen cells, 1391
— response gene mapping, histocompatibility complex, rhesus monkey, 673
— response, genetic control, development of glutamic acid-alanine-tyrosine-specific helper T-cell activity, 50
— response, intestinal, to cholera toxoid, cellular kinetics, 1550
— response to methylcholanthrene-induced fibrosarcoma, 839
— response, net electric charge on antigen and sensitized cell, brain encephalitogen, 701
Immunoglobulin, anti-, induction of histamine secretion, 391
— combining sites, binding properties, antigenic determinants in dextran, 435
—, Fc receptors, Ia-antigens, T lymphocytes, 1403
— G aggregates, immune complexes, and bacterial products in human serum, C1q deviation test, 139
— M, Cμ4 fragment, $\bar{C}1$ fixation and complement activation, 1322
— M-induced tumor cell cytotoxicity, normal thymocytes, 542
—, membrane, abnormal ratio, X-linked B lymphocyte defect, 1316
—, monomeric, binding to Fc receptors, macrophages, 1520
— phenotype alteration, plasmacytoma culture, 998
— suppression, anti-immunoglobulin-induced, B lymphocyte susceptibility, 1052
— synthesis, IgG to IgA shift in clonal differentiation, human leukemic B lymphocytes, 549
Immunoglobulin and T-cell receptors with specificity for same alloantigens, shared idiotypes on, 197
Immunoglobulin-binding factor, suppression of antibody synthesis, 507
Immunostimulation, humoral, variant cell lines, 1133
Immunosuppression, loss of, Friend virus complex in mouse embryo fibroblasts, 936
Inhibition, graft-vs.-host reaction, serum-mediated, 248
Injury, immune, suppression by antigenic modulation, measles virus infection, 864
Interferon, human, enhancement of production by neutral red and chloroquine, inhibition of protein degradation and macromolecular synthesis, 1283
Intestine, immune response to cholera toxoid, cellular kinetics, 1550
I-region-coded determinants, cytotoxic T lymphocytes, third histocompatibility locus, 1477

K

Kidney, glomerulus, human, receptor for complement third component, 1029

L

Leukemias, acute lymphoblastic, unclassified, HL-B alloantigens on cells, 1334
—, human, B lymphocyte clonal differentiation, shift from IgG to IgA synthesis, 549
— virus envelope glycoprotein, mouse thymocytes, G_{IX} antigen, 518
— virus-associated thymocyte surface antigen G_{IX}, 512
Leukemogenicity, retention of, Friend virus complex in mouse embryo fibroblasts, 936
Leukocyte, mixed reaction, and cell-mediated lympholysis, 1301
Levan-binding myeloma proteins, individual and cross-specific idiotypes, 106
Ligands, particle-bound, circumferential attachment to receptors on macrophage plasma membrane, 1263
Lipopolysaccharide, bacterial, immunologic properties, 1488
—, B-cell unresponsiveness to, genetic control, 253
— induction of hypotension and disseminated intravascular coagulation, mediation system, 1570
Lipoprotein, *Escherichia coli* outer membrane, B-lymphocyte mitogen, 473
—, serum regulatory, lymphocyte E rosette inhibitory factor, 1092
Litter size and fetoplacental weight, histocompatibility and maternal immunological status, 180
Liver, F antigen, dominant nonresponsiveness in induction of autoimmunity, 1455
—, regenerating, turnover of ribosomal RNA, 575

Lymph node cells, passive transfer of autoimmune myasthenia, 785
Lymphoblastoid cell lines, alloantigenic expression, 378
Lymphocytes, B, Fc receptor, association of non-*H-2* antigens, 796
—, B, human, glycoprotein and membrane association, 1416
—, B, immune defect, X-linked, 637
—, B, in vitro colony growth, 1534
—, B, mitogen, *Escherichia coli* outer membrane lipoprotein, 473
—, B, murine, stimulation by isolated C3b, 600
—, B, susceptibility to anti-immunoglobulin-induced immunoglobulin suppression, 1052
—, B, X-linked defect, abnormal ratio of membrane immunoglobulin, 1316
—, B and T, cooperation in primary antibody response, 928
—, B and T, histoincompatibility, tetraparental bone marrow chimeras, 989
—, B and T, shared idiotypes, fractionation of specific immunocompetent T lymphocytes, 1231
—, B and T, shared idiotypes, frequency and characteristics of, 1218
—, B and T, specificity for same alloantigens, shared idiotypes on, 197
— E rosette inhibitory factor, regulatory serum lipoprotein, 1092
— function modulation by macrophage culture fluid, 151
— growth and serum albumin, 949
—, mitogenesis, inhibition by immobilized antigen-antibody complexes, 814
—, mixed culture determinants, C2 deficiency, 495
—, mixed cultures, suppression of human cell-mediated lympholysis, 1606
—, mixed reactions, suppression by alloantigen-activated spleen cells, 1391
— and monocytes, human, measles infection, 773
— subpopulations, human, autologous stimulation, 1327
—, B, clonal differentiation, human leukemia, shift from IgG to IgA synthesis, 549
—, T, antigen-sensitized, phytohemagglutinin response, 1017
—, T, antigen-specific, selection and culture of, 90
—, T cytotoxic, binding to target cells, cell surface antigens, 1011
—, T, cytotoxic, functional activation of in absence of DNA synthesis, 622
—, T cytotoxic, human, antigen-specific inhibition of cell-mediated lympholysis, 1339
—, T, cytotoxic, I-region-coded determinants, third histocompatibility locus, 1477
—, T, cytotoxic, sensitivity to hydrocortisone, 790
Lymphocytes, T, Fc receptor, Ia-antigens, and immunoglobulin, 1403
—, T, Fc receptor, mitogen responsiveness, 1041
—, T, mouse, interactions in response to phytohemagglutinin, 1591
—, T, murine, Fc receptor, 611
—, T, reactive to histocompatibility alloantigens, 230
—, T, response to small molecular weight antigen, tolerance to azobenzenearsonate conjugates, 261
—, T, response to small molecular weight antigen, T-T cell interactions, suppression vs. enhancement, 275
—, T, tumor-specific lysis, inhibition by alloantisera, 1023
—, trinitrophenyl-modified, histocompatibility-linked genetic control of cell-mediated lympholysis, 914
Lymphoid, B-, cell lines, detection of specific antigens with human alloantisera, 84
Lympholysis, cell-mediated, antigen-specific inhibition, recognitive specificity of human cytotoxic T lymphocytes, 1339
—, cell-mediated, histocompatibility-linked genetic control, 914
—, cell-mediated, human, suppression in mixed lymphocyte cultures, 1606
—, cell-mediated, and mixed leukocyte reaction, 1301
Lymphoma growth, stimulation by BCG-activated macrophages, 887
—, T-cell, transplantation behavior, 536
Lysine polymers, role in C-reactive protein interactions with complement system, 709
Lysis, malignant cells, by macrophage factor, 1600
—, tumor-specific, T lymphocytes, inhibition by alloantisera, 1023
Lysosome, phago-, formation in colchicine-treated macrophages, 903
Lysosome-phagosome interactions, macrophages infected with virulent tubercle bacilli, 1

M

Macromolecular synthesis and protein degradation, neutral red and chloroquine enhancement of human interferon production, 1283
Macrophage culture fluid, modulation of lymphocyte functions, 151
— factor, lysis of malignant cells, 1600
— Fc receptors, binding of monomeric immunoglobulins, 1520
—, induction of T-helper cells, genetic control of, 460
— killing in vitro of *Trypanosoma cruzi*, absence of in vivo cross-immunity, 299
— plasma membrane receptors, circumferential attachment of particle-bound ligands, 1263

Macrophage culture fluid, secretion of collagenase, 346
— secretion of elastase, 361
— surface fibrinogen/fibrin, role in adherence phenomena, 1377
Macrophages, activated, pinocytosis, 1150
—, BCG-activated, stimulation of lymphoma growth, 887
—, colchicine-treated, phagolysosome formation, 903
—, virulent tubercle bacilli-infected, phagosome-lysosome interactions, 1
Male-specific antigen, cell-mediated immune responses to, 1108
Man, alloantisera, detection of antigens specific for B-lymphoid cell lines, 84
—, B lymphocytes, glycoprotein-membrane association, 1416
—, cell-mediated lympholysis, suppression in mixed lymphocyte cultures, 1606
—, cytotoxic T lymphocytes, antigen-specific inhibition of cell-mediated lympholysis, 1339
—, fibroblasts and amniotic cells, gene defect of acute intermittent porphyria, prenatal diagnosis, 722
—, interferon production, enhancement by neutral red and chloroquine, inhibition of protein degradation and macromolecular synthesis, 1283
—, leukemic B lymphocytes, shift from IgG to IgA synthesis in clonal differentiation, 549
—, lymphocyte growth and serum albumin, 949
—, lymphocyte subpopulations, autologous stimulation, 1327
—, lymphocytes and monocytes, measles infection, 773
—, renal glomerulus, receptor for complement third component, 1029
—, serum, immune complexes, IgG aggregates, and bacterial products, Clq deviation test, 139
—, virus-transformed cells, fibroblast surface antigen, 530
Mapping, immune response genes in histocompatibility complex, rhesus monkey, 673
— of *I* region of *H-2* complex, antigen-specific T-cell factor, 694
Measles infection, human lymphocytes and monocytes, 773
— virus infection, suppression of immune injury by antigenic modulation, 864
Mediation systems, bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation, 1570
Membrane glycoprotein, human B lymphocytes, 1416
— immunoglobulin, abnormal ratio, X-linked B lymphocyte defect, 1316
—, outer, *Escherichia coli*, lipoprotein of, B-lymphocyte mitogen, 473
—, plasma, macrophage, circumferential attachment of particle-bound ligands to receptors, 1263
Memory cells, cytotoxic T lymphocytes, functional activation of in absence of DNA synthesis, 622
Methylcholanthrene-induced fibrosarcoma, cellular immune response to, 839
Migration inhibitory factor, and T cells, 1306
Mitogen, B-lymphocyte, *Escherichia coli* outer membrane lipoprotein, 473
— responsiveness, T lymphocytes with Fc receptor, 1041
Mitogenesis, induction by bacterial lipopolysaccharide in mouse spleen cells, 1488
—, lymphocyte, inhibition by immobilized antigen-antibody complexes, 814
Molecular relationship, private and public *H-2* antigens, determination by antigen redistribution method, 288
Molecules secreted by macrophages, modulation of lymphocyte functions, 151
Monoblast, identification and characterization of, in mononuclear phagocyte colonies, 1180
—, in vitro proliferative characterization, 1200
Monocytes and lymphocytes, human, measles infection, 773
Mouse-protective antibodies against Group B streptococci, 165
Myasthenia, autoimmune, passive transfer by lymph node cells, 785
Myeloma proteins, levan-binding, individual and cross-specific idiotypes, 106

N

Nephritic factor and properdin C3 convertase, 760
Nephrosis, aminonucleoside, glomerular capillary permeability to graded dextrans, 61
Neuraminidase treatment and immune hemolysis, 974
Neutral red and chloroquine enhancement of human interferon production, inhibition of protein degradation and macromolecular synthesis, 1283
Nucleoside, amino-, nephrosis, glomerular capillary permeability to graded dextrans, 61

O

Osteopetrosis, congenital, control by bone marrow and splenic transplants, 651

P

Paralysis, phagocytic, induction by immobilized immune complexes, 827
Particle-bound ligands, circumferential attachment to receptors on macrophage plasma membrane, 1263
Peyer's patch cells, carrier priming of T-cells by antigen feeding, 1425
Phagocyte mononuclear colonies, identification and characterization of monoblasts, 1180

Phagocytosis, circumferential attachment of ligands to receptors, macrophage plasma membrane, 1263
—, selective paralysis induced by immobilized immune complexes, 827
Phagolysosome formation, colchicine-treated macrophages, 903
Phagosome-lysosome interactions, macrophages infected with virulent tubercle bacilli, 1
Phenotype alteration, immunoglobulin, plasmacytoma culture, 998
Phosphorylcholine, anti-, induction of antibody formation by anti-idiotypic antibodies, 1121
Phytohemagglutinin response, antigen-activated T lymphocytes, 1017
—, T lymphocyte, mouse, interactions in response to, 1591
Pinocytosis, activated macrophages, 1150
Placental weight and litter size, histocompatibility and maternal immunological status, 180
Plasmacytoma culture, immunoglobulin phenotype alteration, 998
Plasminogen activators, immunological analysis from normal and transformed hamster cells, 419
Polycations, role in C-reactive protein interactions with complement system, 709
Porphyria, acute intermittent, prenatal diagnosis, gene defect in cultured human fibroblasts and amniotic cells, 722
Prenatal diagnosis, gene defect of acute intermittent porphyria, cultured human fibroblasts and amniotic cells, 722
Properdin and C3 convertase, bound C3b as receptor, 760
—, C3b binding, stabilization of C3b-dependent C3 convertase, 856
Protein antigens, mouse-protective antibodies against Group B streptococci, 165
—, C-reactive, initiation of complement-dependent passive hemolysis, 1065
—, C-reactive, interactions with complement system, role of polycations, 709
— degradation and macromolecular synthesis, neutral red and chloroquine enhancement of human interferon production, 1283
—, myeloma, levan-binding, individual and cross-specific idiotypes, 106
—, Ss, murine, purification of, 664

R

Radiation chimeras, association of immunity and tolerance, 321
— chimeras, cellular adaptation, histocompatibility studies, 120
Receptor, Fc, B lymphocytes, association of non-*H-2* antigens, 796
—, Fc, Ia-antigens, and immunoglobulin, T lymphocytes, 1403
—, Fc, macrophage binding of monomeric immunoglobulins, 1520
Receptor, Fc, murine T lymphocytes, 611
—, Fc, on T lymphocytes, mitogen responsiveness, 1041
—, macrophage plasma membrane, circumferential attachment of particle-bound ligands, 1263
Renal. *See* Kidney.
Rhesus monkey, histocompatibility complex, mapping of immune response genes, 673
Ribonucleic acid, ribosomal, turnover in regenerating liver, 575
Ribonucleic acid-instructed DNA polymerase, brains from Guamanian patients, 483
Ribosome RNA turnover, regenerating liver, 575
Rosette formation, separation of helper cells by, antigen-binding T cells, 1035
— inhibitory factor, lymphocyte E, regulatory serum lipoprotein, 1092

S

Schistosoma mansoni, antieosinophil serum, eosinophil kinetics, 560
— *mansoni* infection, eosinophil role in acquired resistance to, 805
Serum albumin and lymphocyte growth, 949
—, antiallotype, components of, active in release from allotype suppression, 332
—, antieosinophil, eosinophil kinetics in *Schistosomiasis mansoni*, 560
—, antieosinophil, eosinophil role in acquired resistance to *Schistosoma mansoni* infection, 805
— factor, suppression of antibody response, amyloidosis, 236
—, human, immune complexes, IgG aggregates, and bacterial products, Clq deviation test, 139
— inhibition of graft-vs.-host reaction, 248
— lipoprotein, lymphocyte E rosette inhibitory factor, 1092
Skin hypersensitivity reactions, delayed-type, role of vasoactive amines, 732
Specificity, recognitive, human cytotoxic T lymphocytes, antigen-specific inhibition of cell-mediated lympholysis, 1339
—, syngeneic cell-mediated lympholysis, role of *H-2* histocompatibility complex, 403
Spleen cells, alloantigen-activated, suppression of mixed lymphocyte reactions, 1391
— cells, mouse, lipopolysaccharide-induced mitogenesis, 1488
—, Friend virus-infected, surface antigens of cultured tumor cell lines from, 1365
— transplant, control of congenital osteopetrosis, 651
Ss protein, murine, purification of, 664
Streptococci, Group B, mouse-protective antibodies against, 165
Suppression, immune, genetic control, *H-2*-linked dominant control by copolymer glutamic acid-tyrosine, 1447
—, immune, genetic control of, stimulation of

suppressor cells by copolymer glutamic acid-tyrosine, 1436
Surface fibrinogen/fibrin, macrophage, role in adherence phenomena, 1377
Survival, bacterial, phagosome-lysosome interactions, macrophages infected with virulent tubercle bacilli, 1
Syngeneic targets, role of *H-2* histocompatibility complex in determination of specificity of cytotoxic effect, 403

T

T lymphocytes, antigen-sensitized, phytohemagglutinin response, 1017
— lymphocytes, antigen-specific, selection and culture of, 90
— lymphocytes, cytotoxic, binding to target cells, cell surface antigens, 1011
— lymphocytes, cytotoxic, functional activation of in absence of DNA synthesis, 622
— lymphocytes, cytotoxic, human, antigen-specific inhibition of cell-mediated lympholysis, 1339
— lymphocytes, cytotoxic, I-region-coded determinants, third histocompatibility locus, 1477
— lymphocytes, cytotoxic, sensitivity to hydrocortisone, 790
— lymphocytes, Fc receptor, Ia-antigens, and immunoglobulin, 1403
— lymphocytes, Fc receptor, mitogen responsiveness, 1041
— lymphocytes, mouse, interactions in response to phytohemagglutinin, 1591
— lymphocytes, murine, Fc receptor, 611
— lymphocytes reactive to histocompatibility alloantigens, 230
— lymphocytes response to small molecular weight antigen, tolerance to azobenzenearsonate conjugates, 261
— lymphocytes response to small molecular weight antigen, T-T cell interactions, suppression vs. enhancement, 275
— lymphocytes, specific immunocompetent, fractionation of, shared idiotypes on B and T lymphocytes, 1231
— lymphocytes tumor-specific lysis, inhibition by alloantisera, 1023
Target cell binding to cytotoxic T lymphocytes, cell surface antigens, 1011
T- and B-cells, hapten-specific carrier-determined tolerance, 1254
T-cells, antigen binding, separation of helper cells by immune rosette formation, 1035
—, antigen-specific, ontogeny of, 802
— antigen-specific suppressive factor, regulation of antibody response, 1241
—, carrier priming by antigen feeding, Peyer's patch cells, 1425
—, cooperation with B lymphocytes in primary antibody response, 928
—, cooperation with B lymphocytes, tetraparental bone marrow chimeras, 989
T-cells, cytotoxic, histocompatibility against minor antigens, 1349
— factor, antigen-specific, mapping of *I* region of *H-2* complex, 694
— helper activity, glutamic acid-alanine-tyrosine-specific, genetic control of immune response, 50
—, helper, genetic control of macrophage interaction, 460
— lymphomas, transplantation behavior, 536
— and migration inhibitory factor, 1306
— receptors, and immunoglobulins with specificity for same alloantigens, shared idiotypes on, 197
— suppressor activity, feedback induction, 524
Terpolymer glutamic acid-alanine-tyrosine-specific helper T-cell function, genetic control of immune response, 50
Thymocyte antigen G_{IX}, murine leukemia virus envelope glycoprotein, 518
— antigen G_{IX}, murine leukemia virus-associated, 512
—, IgM-induced tumor cell cytotoxicity, 542
Thymus, avian, embryo, histogenesis of cell components, 17
Tolerance to azobenzenearsonate conjugate, T lymphocyte response to small molecular weight antigen, 261
—, cellular basis, neonatally-induced mouse chimeras, 1312
—, hapten-specific carrier-determined, T and B cells, 1254
— and immunity, radiation chimeras, 321
—, immunological, acquired and natural, termination of with specific complexes, 312
—, immunological, induction by antigen feeding, antigen-antibody complexes, 1509
Toxoid, cholera, cellular kinetics of intestinal immune response to, 1550
Transplantation behavior, A. Th and A.Tl T-cell lymphomas, 536
Trinitrophenyl-modified lymphocytes, histocompatibility-linked genetic control of cell-mediated lympholysis, 914
Trypanosoma cruzi, macrophage killing of in vitro, absence of in vivo cross-immunity, 299
— *cruzi*, selective lysis and purification of, 224
Tubercle bacilli, virulent, phagosome-lysosome interactions in macrophages infected with, 1
Tumor lysis by macrophage factor, 1600
Tumors, Friend virus-induced, cell lines derived from, 212
—, Friend virus-induced, spleen cell lines, surface antigens, 1365
Tumor-specific lysis, T lymphocytes, inhibition by alloantisera, 1023
Tyrosine-alanine-glutamic acid-specific helper T-cell function, genetic control of immune

response, 50
Tyrosine-glutamic acid copolymer, *H-2*-linked dominant genetic control of immune suppression, 1447
— acid copolymer, stimulation of suppressor cells, 1436

V

Vasoactive amines, delayed-type hypersensitivity skin reactions, 732
Virus, Friend, cell lines derived from tumors induced by, 212
—, Friend, complex, continuous replication of in mouse embryo fibroblasts, retention of leukemogenicity and loss of immunosuppression, 936
—, Friend, infected spleen, surface antigens of cultured tumor cell lines from, 1365
—, leukemia, envelope glycoprotein, mouse thymocytes, G_{IX} antigen, 518
—, leukemia, thymocyte surface antigen G_{IX}, 512
—, measles infection, suppression of immune injury by antigenic modulation, 864

X

X-linked B lymphocyte defect, abnormal ratio of membrane immunoglobulin, 1316
— B lymphocyte immune defect, 637

Statement of Ownership, Management, and Circulation required by Act of 12 August 1970; Section 3685, Title 39, United States Code: The Journal of Experimental Medicine. Published monthly at 1230 York Ave., New York 10021, by The Rockefeller University Press, New York 10021. Editors: Zanvil A. Cohn, James G. Hirsch, Richard M. Krause, Henry G. Kunkel, Maclyn McCarty, The Rockefeller University, New York 10021. Owned by The Rockefeller University, New York 10021, nonprofit corporation, authorized to mail at special rates. Purpose, function, and nonprofit status of the organization and the exempt status for Federal income tax purposes have not changed during the preceding 12 months. Following statistics represent 12 month average and number nearest to date of filing: copies printed for each issue, 3920; sales through dealers, street vendors, counter sales, 0; mail subscriptions, 3541. Total paid circulation, 3541; free distribution, 73; office use, left-over, unaccounted, spoiled, 306; net press run, 3920. Single issue nearest filing date October 1975.